Patents by Inventor Douglas Pippin

Douglas Pippin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060211738
    Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma.
    Type: Application
    Filed: January 13, 2006
    Publication date: September 21, 2006
    Inventors: Scott Mitchell, Mihaela Danca, Peter Blomgren, Robert DeSimone, Douglas Pippin
  • Publication number: 20060199846
    Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma.
    Type: Application
    Filed: January 13, 2006
    Publication date: September 7, 2006
    Inventors: Scott Mitchell, Mihaela Danca, Peter Blomgren, Robert DeSimone, Douglas Pippin, David Brittelli
  • Publication number: 20060183746
    Abstract: Certain compounds, such as at least one chemical entity choen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, may in certain embodiments be used to treat patients suffering from one or more diseases responsive to inhibition of tyrosine kinase activity. The diseases may, for instance, be responsive to inhibition of Btk activity and/or B-cell proliferation. Example diseases include cancer, an autoimmune and/or inflammatory disease, and an acute inflammatory reaction.
    Type: Application
    Filed: December 2, 2005
    Publication date: August 17, 2006
    Inventors: Kevin Currie, Robert Desimone, Scott Mitchell, Douglas Pippin, James Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Patent number: 7015227
    Abstract: A composition comprises a compound of Formula 1: a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein W is a nitrogen-substituted 5- or 6-membered monocyclic ring. The compounds are of utility as modulators of kinase activity.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: March 21, 2006
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: James W. Darrow, Robert W. DeSimone, Douglas A. Pippin, Scott A. Mitchell
  • Publication number: 20050288295
    Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, and prodrugs thereof. Methods of treating or preventing disorders in which aberrant kinase activity is implicated, pharmaceutically compositions, and methods for detecting the presence kinases in cells or biological preparations and for identifying kinases of therapeutic interest.
    Type: Application
    Filed: November 10, 2004
    Publication date: December 29, 2005
    Inventors: Kevin Currie, Robert DeSimone, Douglas Pippin, James Darrow, Scott Mitchell
  • Patent number: 6919340
    Abstract: A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.
    Type: Grant
    Filed: April 21, 2003
    Date of Patent: July 19, 2005
    Assignee: Cellular Genomics, Inc.
    Inventors: Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell
  • Publication number: 20050101604
    Abstract: Compounds of Formula I and all pharmaceutically acceptable forms thereof, are described herein. The variables R1, R2, R3, Z2, and Q, shown in Formula I are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Application
    Filed: June 30, 2004
    Publication date: May 12, 2005
    Inventors: Kevin Currie, Robert DeSimone, Scott Mitchell, Douglas Pippin
  • Publication number: 20050090499
    Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Application
    Filed: June 4, 2004
    Publication date: April 28, 2005
    Inventors: Kevin Currie, Robert DeSimone, Scott Mitchell, Douglas Pippin, James Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Publication number: 20050085484
    Abstract: Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically-acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound of the invention to decrease the symptoms or slow the progression of these diseases or disorders.
    Type: Application
    Filed: August 11, 2004
    Publication date: April 21, 2005
    Inventors: Scott Mitchell, Robert DeSimone, James Darrow, Douglas Pippin, M. Danca
  • Publication number: 20050054649
    Abstract: This invention pertains to compounds of Formula I: and the pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 10, 2004
    Publication date: March 10, 2005
    Inventors: Kevin Currie, Robert DeSimone, Douglas Pippin, James Darrow, Scott Mitchell
  • Publication number: 20050054648
    Abstract: This invention pertains to compounds of Formula I: and all pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma.
    Type: Application
    Filed: February 10, 2004
    Publication date: March 10, 2005
    Inventors: Scott Mitchell, Kevin Currie, Robert DeSimone, Douglas Pippin
  • Publication number: 20040082627
    Abstract: Compound having Formula 1: 1
    Type: Application
    Filed: June 23, 2003
    Publication date: April 29, 2004
    Inventors: James W. Darrow, Robert W. DeSimone, Douglas A. Pippin, Scott A. Mitchell
  • Publication number: 20040067951
    Abstract: A novel composition comprises a compound of Formula 1 1
    Type: Application
    Filed: September 9, 2003
    Publication date: April 8, 2004
    Inventors: Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell, Kevin S. Currie
  • Publication number: 20040053927
    Abstract: A composition comprises a compound of Formula 1: 1
    Type: Application
    Filed: June 23, 2003
    Publication date: March 18, 2004
    Inventors: James W. Darrow, Robert W. DeSimone, Douglas A. Pippin, Scott A. Mitchell
  • Publication number: 20030212073
    Abstract: A novel composition comprises a compound of Formula 1 1
    Type: Application
    Filed: April 21, 2003
    Publication date: November 13, 2003
    Inventors: Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell